JP2015078201A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078201A5
JP2015078201A5 JP2014233012A JP2014233012A JP2015078201A5 JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5 JP 2014233012 A JP2014233012 A JP 2014233012A JP 2014233012 A JP2014233012 A JP 2014233012A JP 2015078201 A5 JP2015078201 A5 JP 2015078201A5
Authority
JP
Japan
Prior art keywords
solid pharmaceutical
group
acid
pharmaceutical composition
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014233012A
Other languages
English (en)
Japanese (ja)
Other versions
JP6391436B2 (ja
JP2015078201A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014233012A priority Critical patent/JP6391436B2/ja
Priority claimed from JP2014233012A external-priority patent/JP6391436B2/ja
Publication of JP2015078201A publication Critical patent/JP2015078201A/ja
Publication of JP2015078201A5 publication Critical patent/JP2015078201A5/ja
Application granted granted Critical
Publication of JP6391436B2 publication Critical patent/JP6391436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014233012A 2013-04-25 2014-11-17 固形医薬組成物 Active JP6391436B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014233012A JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013092171 2013-04-25
JP2013092171 2013-04-25
JP2014233012A JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014541237A Division JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Publications (3)

Publication Number Publication Date
JP2015078201A JP2015078201A (ja) 2015-04-23
JP2015078201A5 true JP2015078201A5 (enExample) 2017-06-15
JP6391436B2 JP6391436B2 (ja) 2018-09-19

Family

ID=51791434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014541237A Active JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物
JP2014233012A Active JP6391436B2 (ja) 2013-04-25 2014-11-17 固形医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014541237A Active JP5651812B1 (ja) 2013-04-25 2014-04-24 固形医薬組成物

Country Status (7)

Country Link
US (1) US9603804B2 (enExample)
EP (1) EP2990038B1 (enExample)
JP (2) JP5651812B1 (enExample)
CN (1) CN105338982B (enExample)
CA (1) CA2910112C (enExample)
ES (1) ES2768651T3 (enExample)
WO (1) WO2014174846A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2016063542A1 (ja) * 2014-10-23 2016-04-28 杏林製薬株式会社 固形医薬組成物
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
EP3305294A4 (en) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
JP6675396B2 (ja) * 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
JP6031217B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ, インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法
US20210308117A1 (en) 2020-03-20 2021-10-07 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
KR940000232B1 (ko) 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2512302B2 (ja) 1986-03-19 1996-07-03 中外製薬株式会社 ニコランジル安定化製剤の製造方法
ES2052245T3 (es) 1988-12-28 1994-07-01 Taisho Pharmaceutical Co Ltd Procedimiento de dispersion de las tensiones durante una operacion de formacion de tabletas.
JP2682353B2 (ja) 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (enExample) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
JP2006111639A (ja) 1993-10-21 2006-04-27 Takeda Chem Ind Ltd 医薬用錠剤
JPH08175996A (ja) 1994-12-22 1996-07-09 Taiyo Yakuhin Kogyo Kk ニコランジル安定化固形製剤の製法
JP3119801B2 (ja) 1995-09-28 2000-12-25 武田薬品工業株式会社 ビタミン含有組成物の安定化方法
JPH10245335A (ja) 1997-02-28 1998-09-14 Dainippon Pharmaceut Co Ltd 圧力に不安定な薬物の打錠方法及びそれに用いられる湿潤顆粒
CA2322432C (en) 1998-03-03 2005-12-20 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
EA006974B1 (ru) 2001-02-27 2006-06-30 Ранбакси Лабораторис Лимитед Оральная фармацевтическая композиция цефподоксима проксетила
US7219132B2 (en) 2001-03-30 2007-05-15 Space Systems/Loral Dynamic resource allocation architecture for differentiated services over broadband communication networks
AU2003213335B8 (en) * 2002-03-18 2009-04-02 Kyorin Pharmaceutical Co., Ltd. 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium
EP1459739B1 (en) 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
CN100410249C (zh) * 2003-09-10 2008-08-13 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物
US20090117205A1 (en) 2004-07-02 2009-05-07 Daiichi Pharmaceutical Co., Ltd Quinolone-containing medicinal composition
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
AR053662A1 (es) 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
ATE518526T1 (de) 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
JP2006298811A (ja) 2005-04-20 2006-11-02 Taiyo Yakuhin Kogyo Kk ゲル化抑制製剤の設計
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2013145749A1 (ja) * 2012-03-29 2013-10-03 杏林製薬株式会社 カプセル製剤
JP6062422B2 (ja) * 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent

Similar Documents

Publication Publication Date Title
JP2015078201A5 (enExample)
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
ZA201507958B (en) New somatostatin receptor subtype 4 (sstr4)agonists
JP2015110646A5 (enExample)
JP2018531941A5 (enExample)
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
JP2015063536A5 (enExample)
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
MY160785A (en) Manufacturing process for pyrimidine derivatives
SG10201806565SA (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2021006790A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
HRP20241103T1 (hr) 2,4-di-(skupina koja sadrži dušik)-supstituirani pirimidinski spoj i postupak pripreme i njegova upotreba
JP2016531126A5 (enExample)
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EA201691538A1 (ru) Способ получения солей вортиоксетина
JP2017501141A5 (enExample)
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2016001095A (es) Sales de dasatinib en forma cristalina.
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation